https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-01-01 / Methods Mol. Biol. 2019;1884:317-333
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-01-01 / Methods Mol. Biol. 2019;1884:317-3332019-01-01 00:00:002019-01-01 00:00:00A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-01-01 / Klin Onkol 2019;32(1):70-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-01-01 / Klin Onkol 2019;32(1):70-742019-01-01 00:00:002019-01-01 00:00:00Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Front Immunol 2018;9:2759
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Front Immunol 2018;9:27592018-12-05 00:00:002018-12-05 00:00:00Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Acta Neuropathol Commun 2018 12;6(1):135
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Acta Neuropathol Commun 2018 12;6(1):1352018-12-05 00:00:002018-12-05 00:00:00Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Blood Rev. 2019 03;34:67-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Blood Rev. 2019 03;34:67-832018-12-05 00:00:002018-12-05 00:00:00Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-04 / Clin. Cancer Res. 2019 Mar;25(5):1494-1504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-04 / Clin. Cancer Res. 2019 Mar;25(5):1494-15042018-12-04 00:00:002018-12-04 00:00:00Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-03 / Front Immunol 2018;9:2804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-03 / Front Immunol 2018;9:28042018-12-03 00:00:002018-12-03 00:00:00Current State of Dendritic Cell-Based Immunotherapy: Opportunities for Antigen Loading of Different DC Subsets?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-11-23 / Vaccines (Basel) 2018 Nov;6(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-11-23 / Vaccines (Basel) 2018 Nov;6(4)2018-11-23 00:00:002018-11-23 00:00:00Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-7802018-11-21 00:00:002020-11-30 10:25:48Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-11-12 / Cancers (Basel) 2018 Nov;10(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-11-12 / Cancers (Basel) 2018 Nov;10(11)2018-11-12 00:00:002019-02-15 08:47:42The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage
